Showing results (331-340 of 498) with videos related to
Sort By:
Pageof 50
European Heart Journal|June 30, 2012
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspectiveClaudio Rapezzi, Candida Cristina Quarta, Laura Obici, et al.Nature Communications|November 17, 2022
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelterTim Schulte, Antonio Chaves-Sanjuan, Giulia Mazzini, et al.EMBO Reports|May 21, 2011
Antagonistic regulation of EMT by TIF1γ and Smad4 in mammary epithelial cellsCédric Hesling, Laurent Fattet, Guillaume Teyre, et al.Journal of Diabetes Science and Technology|February 11, 2010
Fabrication of polymer microneedles using a two-photon polymerization and micromolding processShaun D Gittard, Aleksandr Ovsianikov, Nancy A Monteiro-Riviere, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|November 4, 2025
Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidisGiuseppe Damiano Sanna, Valeria Anna Di Simone, Paolo Milani, et al.Blood|January 29, 2017
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicityLaura Oliva, Ugo Orfanelli, Massimo Resnati, et al.Neurobiology of Disease|March 20, 2012
Specific inhibition of the JNK pathway promotes locomotor recovery and neuroprotection after mouse spinal cord injuryMariaelena Repici, Xiaoru Chen, Marie-Pierre Morel, et al.Journal of Experimental & Clinical Cancer Research : CR|October 29, 2020
Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemiaWalaa Darwiche, Cathy Gomila, Hakim Ouled-Haddou, et al.Leukemia|July 25, 2018
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasiasMaria Gavriatopoulou, Pellegrino Musto, Jo Caers, et al.Blood|May 13, 2011
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 studyDonna E Reece, Ute Hegenbart, Vaishali Sanchorawala, et al.Pageof 50